ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.856,66
-0,33%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) News

SNGX

Soligenix (SNGX)

Soligenix Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SNGX
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
17/05/202422h09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
16/05/202413h30PR Newswire (US)Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeNASDAQ:SNGXSoligenix Inc
15/05/202422h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
10/05/202422h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
10/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
10/05/202413h30PR Newswire (US)Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
06/05/202413h30PR Newswire (US)Soligenix to Present at Upcoming ConferencesNASDAQ:SNGXSoligenix Inc
25/04/202413h30PR Newswire (US)Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaNASDAQ:SNGXSoligenix Inc
18/04/202414h30PR Newswire (US)Soligenix Announces Pricing of $4.75 Million Public OfferingNASDAQ:SNGXSoligenix Inc
15/04/202413h30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionNASDAQ:SNGXSoligenix Inc
11/04/202413h30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionNASDAQ:SNGXSoligenix Inc
03/04/202413h30PR Newswire (US)Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyNASDAQ:SNGXSoligenix Inc
15/03/202412h30PR Newswire (US)Soligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
08/02/202413h30PR Newswire (US)Soligenix Announces Formation of Behçet's Disease Medical Advisory BoardNASDAQ:SNGXSoligenix Inc
25/01/202413h30PR Newswire (US)Soligenix to Present at The Microcap ConferenceNASDAQ:SNGXSoligenix Inc
08/01/202413h30PR Newswire (US)FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
04/01/202413h30PR Newswire (US)Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisNASDAQ:SNGXSoligenix Inc
02/01/202413h30PR Newswire (US)Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesNASDAQ:SNGXSoligenix Inc
22/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
18/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNGXSoligenix Inc
15/12/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
15/12/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
15/12/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
15/12/202322h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
15/12/202322h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
08/12/202323h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
08/12/202323h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
08/12/202323h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
08/12/202323h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNGX

Kürzlich von Ihnen besucht

BOV
AALL34M
American Airlines
ASX
ASNNC
Anson Resources
COIN
GDCOGBP
COIN
MNTBTC
TSXV
CYU
ASX
WF8
BOV
N1TR34
Northern
COIN
RELLUST
ReaNance
ASX
FXUKOW
BIT
IQCT
Lyxor Msci Smart Cts Esg...
BIT
UB4QE3
Unicredit Bank
BIT
P117R1
Bnp Paribas Issuance
COIN
CYBERGBP
CyberConnect
USOTC
DVOUF
Distribusi Voucher Nusan... (GM)
COIN
FUZZBTC
TSXV
OGI
OrganiGram
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten